-
Fenofibrate and the PPARα–YAP Translation Gap
2026-09-15
Fenofibrate is more than a lipid metabolism tool: it offers a pharmacological route to interrogate how PPARα activation intersects with YAP-dependent liver growth, aging biology, and cancer phenotypes. This article outlines a translational workflow that prioritizes mechanism, exposure control, and interpretation beyond single-point viability data.
-
IWR-1-endo Workflows for Wnt Signaling Control
2026-09-15
Build reproducible Wnt/β-catenin experiments with IWR-1-endo, from DLD-1 proliferation assays to regeneration models. This guide combines mechanism-based dosing, practical controls, single-cell-inspired assay design, and troubleshooting for colorectal cancer research and stem-cell studies.
-
Cyclosporin as a Mechanistic Assay Probe
2026-09-14
Cyclosporin A is more than a calcineurin inhibitor: it is a mechanistic probe for cyclophilin-dependent T-cell signaling and mitochondrial stress. This guide translates genetic evidence into better experimental controls for immunosuppression, signaling, and mitochondrial assays.
-
Capsazepine Workflows for TRPV1 Research
2026-09-14
Capsazepine provides a practical pharmacological handle for separating TRPV1-dependent nociception from calcium signaling, TRPM8 activity, and downstream apoptosis phenotypes. This guide combines assay-ready preparation, model selection, quantitative starting conditions, and troubleshooting for pain, ion-channel, and cancer research.
-
Liproxstatin-1 HCl: Ferroptosis Research Guide
2026-09-13
Liproxstatin-1 HCl is a selective ferroptosis inhibitor that suppresses lipid peroxidation, with a reported cellular IC50 of 22 nM. Its use spans ferroptosis assays and preclinical acute renal failure and hepatic ischemia/reperfusion injury models, but it does not broadly block apoptosis or hydrogen peroxide toxicity.
-
Vancomycin Hydrochloride: Mechanism & Research Use
2026-09-12
Vancomycin hydrochloride is a glycopeptide antibacterial agent and bacterial cell wall synthesis inhibitor used mainly in Gram-positive research. Its defined D-Ala-D-Ala target, product-specific handling data, and established role in selective microbiology workflows make it useful for antibiotic resistance assay design and bacterial susceptibility testing.
-
Rosiglitazone in Beige-Fat Assay Design
2026-09-12
Rosiglitazone (Brl-49653) provides a mechanistic PPARγ control for studying adipocyte differentiation, insulin sensitivity, and thermogenic remodeling. This guide connects the compound to the SEMA3E–β-catenin findings while emphasizing assay design, interpretation, and evidence boundaries.
-
HOXC8, Caspase-1, and Pyroptosis in NSCLC
2026-09-11
The reference study identifies HOXC8 as a context-dependent oncogenic factor in non-small cell lung cancer (NSCLC) that prevents pyroptotic death by repressing CASP1 transcription through HDAC1/2 recruitment. Its findings connect transcriptional control of inflammatory caspase abundance with tumor-cell survival and suggest that disrupting the HOXC8–HDAC–CASP1 axis may provide a mechanistically distinct approach to studying lung tumorigenesis.
-
AI-10-49 Workflows for inv(16) AML Research
2026-09-11
AI-10-49 enables a mechanism-led workflow that connects CBFβ-SMMHC target engagement with RUNX1 chromatin recovery, leukemia cell proliferation inhibition, and downstream MYCN–eIF4G1 biology. This guide translates those findings into practical cell, chromatin, and in vivo leukemia mouse model experiments while addressing solubility, assay timing, and interpretation risks.
-
WP1066: JAK2/STAT3 Inhibitor Workflows
2026-09-10
WP1066 is a cell-permeable pathway probe for linking JAK2/STAT3 signaling to cancer-cell growth, apoptosis, and macrophage-state changes. This practical guide separates established oncology applications from emerging scaffold-based regeneration studies and provides concentration, timing, readout, and troubleshooting strategies.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-10
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support incorporating ATRX status into preclinical design and interpretation of targeted-therapy studies, while underscoring the need to validate these findings beyond cell-based models.
-
Metformin Hydrochloride: From Metabolism to Tendon HO
2026-09-09
Metformin Hydrochloride is more than a glucose-metabolism tool: it enables mechanism-aware studies of AMPK, redox control, and tendon heterotopic ossification. This article translates recent Nr4a1/Wnt/β-catenin findings into practical assay-design decisions.
-
MK-5108 (VX-689) Aurora A Assays
2026-09-09
MK-5108, also known as VX-689, enables selective Aurora A interrogation in biochemical, cell-based, and tumor-model workflows. This guide translates retinoblastoma findings into practical assay design, dose selection, controls, and troubleshooting strategies while distinguishing research evidence from experimental recommendations.
-
HyperScribe™ T7 High Yield RNA Kit for ac4C
2026-09-08
The HyperScribe T7 High Yield RNA Synthesis Kit enables controlled RNA production for ac4C-focused assay design, including capped RNA synthesis and biotinylated RNA synthesis. This article explains how to translate NAT10–ac4C findings in mouse oocytes into better controls, probe strategies, and interpretation of in vitro transcription experiments.
-
Polybrene Workflow Guide for Viral Transduction
2026-09-08
Build more reproducible lentiviral, retroviral, and lipid-mediated DNA delivery workflows with Polybrene while controlling exposure-related cytotoxicity. This guide also explains how delivery optimization can support engineered-cell assays inspired by emerging FBXO22 targeted protein degradation research.